#USA #New York #securities violations #Capricor Therapeutics #Law Group

Recent Lawsuit Against Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., listed on NASDAQ under the symbol CAPR, is currently facing legal repercussions due to alleged violations of securities laws. A class action lawsuit has been initiated against the company, drawing attention to possible misleading information released during an important period for shareholders. The DJS Law Group is actively encouraging affected investors to reach out for advice and support regarding their rights.

Overview of the Allegations

The lawsuit centers around claims that Capricor made false and misleading statements during a significant timeframe, particularly focusing on their drug candidate, deramiocel. According to allegations, the company suggested that this drug was making substantial progress towards receiving approval from the FDA. However, it appears that behind the scenes, Capricor was aware of negative data stemming from their Phase 2 HOPE-2 trial, which painted a starkly different picture than what was communicated publicly.

Class Period Information

The class period specified in the lawsuit ranges from October 9, 2024, to July 10, 2025, with a deadline for joining the class action set for September 15, 2025. Shareholders who acquired CAPR shares within this timeframe are especially urged to connect with DJS Law Group, as doing so may enable them to participate in recovering their potential losses.

Next Steps for Investors

Investors who register as shareholders for CAPR during the specified class period will receive continual updates on the case's developments through a dedicated portfolio monitoring service. This program is designed to keep shareholders informed and engaged without incurring any fees or obligations.

Why DJS Law Group?

DJS Law Group is recognized for its commitment to promoting investor retention through comprehensive support and proactive litigation strategies. Specializing in securities class actions and related corporate governance issues, they have built a reputation for effective representation. Their client base includes some of the most influential hedge funds and asset managers worldwide, underscoring the weight and importance of the claims handled by the firm.

If you have faced financial loss due to your investment in Capricor Therapeutics, this is a critical moment to assess your legal options. Joining the class action can be a viable path toward financial recovery and holding accountable those responsible for any misleading conduct.

Conclusion

As the legal proceedings unfold, investors are advised to remain vigilant and informed. This lawsuit represents not only potential financial implications for shareholders of Capricor Therapeutics but also highlights the importance of transparency and accountability in the healthcare sector. For further assistance and to explore your options, do not hesitate to reach out to DJS Law Group.